General anesthetics and molecular mechanisms of unconsciousness

International Anesthesiology Clinics

Volumn 46, Issue 3, 2008, Pages 43-53

  Forman, Stuart A ^a   Chin, Victor A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ANESTHETIC AGENT; BARBITURIC ACID DERIVATIVE; CANNABINOID RECEPTOR; CYCLOPROPANE; DESFLURANE; DEXMEDETOMIDINE; ENFLURANE; ETOMIDATE; GLYCINE RECEPTOR; HALOTHANE; INHALATION ANESTHETIC AGENT; INTRAVENOUS ANESTHETIC AGENT; ISOFLURANE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINIC RECEPTOR; NITRIC OXIDE; POTASSIUM CHANNEL; PROPOFOL; SEVOFLURANE; XENON;

AMNESIA; ARTICLE; BLOOD PRESSURE REGULATION; CAENORHABDITIS ELEGANS; CONCENTRATION RESPONSE; CONSCIOUSNESS; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ELECTROENCEPHALOGRAPHY; GENE MUTATION; GENERAL ANESTHESIA; HUMAN; HYPNOSIS; IMMOBILIZATION; INTRAVENOUS ANESTHESIA; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BRAIN; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG EFFECT; REVIEW; UNCONSCIOUSNESS;

ANESTHESIA, GENERAL; ANESTHETICS; ANIMALS; BRAIN; CONSCIOUSNESS; ELECTROENCEPHALOGRAPHY; HUMANS; UNCONSCIOUSNESS;

EID: 53449095367     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/AIA.0b013e3181755da5     Document Type: Article

References (61)

1. Nuland SB. Doctors: the Biography of Medicine. 1st ed. New York: Knopf; 1988.
2. Kissin I. A concept for assessing interactions of general anesthetics. Anesth Analg. 1997;85:204-210.
3. Grasshoff C, Rudolph U, Antkowiak B. Molecular and systemic mechanisms of general anaesthesia: the "multi-site and multiple mechanisms" concept. Curr Opin Anaesthesiol. 2005;18:386-391.
4. Mashour GA, Forman SA, Campagna JA. Mechanisms of general anesthesia: from molecules to mind. Best Pract Res Clin Anaesthesiol. 2005;19:349-364.
5. Woodbridge PD. Changing concepts concerning depth of anesthesia. Anesthesiology. 1957;18:536-550.
6. Eger EI II. Age, minimum alveolar anesthetic concentration, and minimum alveolar anesthetic concentration-awake. Anesth Anal. 2001;93:947-953.
7. Forman SA. Awareness during general anesthesia: concepts and controversies. Semin Anesth, Perioperat Med Pain. 2006;25:211-218.
8. Grasshoff C, Drexler B, Rudolph U, et al. Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12:3665-3679.
9. Solt K, Forman SA. Correlating the clinical actions and molecular mechanisms of general anesthetics. Curr Opin Anaesthesiol. 2007;20:300-306.
10. Smith C, McEwan AI, Jhaveri R, et al. The interaction of fentanyl on the Cp50 of propofol for loss of consciousness and skin incision. Anesthesiology. 1994;81: 820-828.
11. Kuizenga K, Wierda JM, Kalkman CJ. Biphasic EEG changes in relation to loss of consciousness during induction with thiopental, propofol, etomidate, midazolam or sevoflurane. Br J Anaesth. 2001;86:354-360.
12. Lynch C III, Baum J, Tenbrinck R. Xenon anesthesia. Anesthesiology. 2000;92: 865-868.
13. Goto T, Nakata Y, Ishiguro Y, et al. Minimum alveolar concentration-awake of Xenon alone and in combination with isoflurane or sevoflurane. Anesthesiology. 2000;93:1188-1193.
14. Anderson RE, Jakobsson JG. Entropy of EEG during anaesthetic induction: a comparative study with propofol or nitrous oxide as sole agent. Br J Anaesth. 2004;92: 167-170.
15. Rampil IJ, Kim JS, Lenhardt R, et al. Bispectral EEG index during nitrous oxide administration. Anesthesiology. 1998;89:671-677.
16. Laitio RM, Kaskinoro K, Sarkela MO, et al. Bispectral index, entropy, and quantitative electroencephalogram during single-agent xenon anesthesia. Anesthesiology. 2008;108:63-70.
17. Goto T, Nakata Y, Saito H, et al. Bispectral analysis of the electroencephalogram does not predict responsiveness to verbal command in patients emerging from xenon anaesthesia. Br J Anaesth. 2000;85:359-363.
18. Campagna JA, Miller KW, Forman SA. Mechanisms of actions of inhaled anesthetics. N Engl J Med. 2003;348:2110-2124.
19. Whiting PJ. The GABA-A receptor gene family: new targets for therapeutic intervention. Neurochem Int. 1999;34:387-390.
20. Husain SS, Ziebell MR, Ruesch D, et al. 2-(3-methyl-3H-diaziren-3-yl) ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: a derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels. J Med Chem. 2003;46:1257-1265.
21. Hill-Venning C, Belelli D, Peters JA, et al. Subunit-dependent interaction of the general anaesthetic etomidate with the gamma-aminobutyric acid type A receptor. Br J Pharmacol. 1997;120:749-756.
22. Belelli D, Lambert JJ, Peters JA, et al. The interaction of the general anesthetic etomidate with the gamma-aminobutyric acid type A receptor is influenced by a single amino acid. Proc Natl Acad Sci USA. 1997;94:11031-11036.
23. Jurd R, Arras M, Lambert S, et al. General anesthetic actions in vivo strongly attenuated by a point mutation in the GABA(A) receptor beta3 subunit. FASEB J. 2003;17:250-252.
24. Liao M, Sonner JM, Husain SS, et al. R (+) etomidate and the photoactivable R (+) azietomidate have comparable anesthetic activity in wild-type mice and comparably decreased activity in mice with a N265M point mutation in the gamma-aminobutyric acid receptor beta3 subunit. Anesth Anal. 2005;101:131-135.
25. Zeller A, Arras M, Jurd R, et al. Identification of a molecular target mediating the general anesthetic actions of pentobarbital. Mol Pharmacol. 2007;71:852-859.
26. Reynolds DS, Rosahl TW, Cirone J, et al. Sedation and anesthesia mediated by distinct GABA(A) receptor isoforms. J Neurosci. 2003;23:8608-8617.
27. Patel S, Wohlfeil ER, Rademacher DJ, et al. The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003;139:1005-1013.
28. Jevtovic-Todorovic V, Todorovic SM, Mennerick S, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med. 1998;4:460-463.
29. Franks NP, Dickinson R, de Sousa SL, et al. How does xenon produce anaesthesia? Nature. 1998;396:324.
30. Zeilhofer HU, Swandulla D, Geisslinger G, et al. Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons. Eur J Pharmacol. 1992;213:155-158.
31. Raines DE, Claycomb RJ, Scheller M, et al. Nonhalogenated alkane anesthetics fail to potentiate agonist actions on two ligand-gated ion channels. Anesthesiology. 2001;95: 470-477.
32. Petrenko AB, Yamakura T, Fujiwara N, et al. Reduced sensitivity to ketamine and pentobarbital in mice lacking the N-methyl-D-aspartate receptor GluRepsilon1 subunit. Anesth Analg. 2004;99:1136-1140.
33. Sato Y, Kobayashi E, Hakamata Y, et al. Chronopharmacological studies of ketamine in normal and NMDA epsilon1 receptor knockout mice. Br J Anaesth. 2004;92:859-864.
34. Sato Y, Kobayashi E, Murayama T, et al. Effect of N-methyl-D- aspartate receptor epsilon1 subunit gene disruption of the action of general anesthetic drugs in mice. Anesthesiology. 2005;102:557-561.
35. Nagele P, Metz LB, Crowder CM. Nitrous oxide [N(2)O] requires the N-methyl-D-aspartate receptor for its action in Caenorhabditis elegans. Proc Natl Acad Sci USA. 2004;101:8791-8796.
36. Nagele P, Metz LB, Crowder CM. Xenon acts by inhibition of non-N-methyl-D-aspartate receptor-mediated glutamatergic neurotransmission in Caenorhabditis elegans. Anesthesiology. 2005;103:508-513.
37. Yamakura T, Harris RA. Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels. Comparison with isoflurane and ethanol. Anesthesiology. 2000;93:1095-1101.
38. Coates KM, Flood P. Ketamine and its preservative, benzethonium chloride, both inhibit human recombinant alpha7 and alpha4beta2 neuronal nicotinic acetylcholine receptors in Xenopus oocytes. Br J Pharmacol. 2001;134:871-879.
39. Friederich P, Dybek A, Urban BW. Stereospecific interaction of ketamine with nicotinic acetylcholine receptors in human sympathetic ganglion-like SH-SY5Y cells. Anesthesiology. 2000;93:818-824.
40. Raines DE, Claycomb RJ, Forman SA. Nonhalogenated anesthetic alkanes and perhalogenated nonimmobilizing alkanes inhibit alpha(4)beta(2) neuronal nicotinic acetylcholine receptors. Anesth Analg. 2002;95:573-577.
41. Gruss M, Bushell TJ, Bright DP, et al. Two-pore-domain K+ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane. Mol Pharmacol. 2004;65:443-452.
42. Franks NP, Honore E. The TREK K2P channels and their role in general anaesthesia and neuroprotection. Trends Pharmacol Sci. 2004;25:601-608.
43. Heurteaux C, Guy N, Laigle C, et al. TREK-1, a K+ channel involved in neuroprotection and general anesthesia. EMBO J. 2004;23:2684-2695.
44. Quinlan JJ, Homanics GE, Firestone LL. Anesthesia sensitivity in mice that lack the beta3 subunit of the gamma-aminobutyric acid type A receptor. Anesthesiology. 1998;88:775-780.
45. Borghese CM, Werner DF, Topf N, et al. An isoflurane- and alcohol-insensitive mutant GABA(A) receptor alpha(1) subunit with near-normal apparent affinity for GABA: characterization in heterologous systems and production of knockin mice. J Pharmacol Exp Ther. 2006;319:208-218.
46. Sonner JM, Werner DF, Elsen FP, et al. Effect of isoflurane and other potent inhaled anesthetics on minimum alveolar concentration, learning, and the righting reflex in mice engineered to express alpha1 gamma-aminobutyric acid type A receptors unresponsive to isoflurane. Anesthesiology. 2007;106:107-113.
47. Patel AJ, Honore E, Lesage F, et al. Inhalational anesthetics activate two-pore-domain background K+ channels. Nat Neurosci. 1999;2:422-426.
48. Linden AM, Sandu C, Aller MI, et al. TASK-3 knockout mice exhibit exaggerated nocturnal activity, impairments in cognitive functions, and reduced sensitivity to inhalation anesthetics. J Pharmacol Exp Ther. 2007;323:924-934.
49. Gerstin KM, Gong DH, Abdallah M, et al. Mutation of KCNK5 or Kir3.2 potassium channels in mice does not change minimum alveolar anesthetic concentration. Anesth Analg. 2003;96:1345-1349.
50. Dildy-Mayfield JE, Eger EI II, Harris RA. Anesthetics produce subunit-selective actions on glutamate receptors. J Pharm Exp Ther. 1996;276:1058-1065.
51. Sonner JM, Vissel B, Royle G, et al. The effect of three inhaled anesthetics in mice harboring mutations in the GluR6 (kainate) receptor gene. Anesth Analg. 2005;101:143-148.
52. Flood P, Role LW. Neuronal nicotinic acetylcholine receptor modulation by general anesthetics. Toxicol Lett. 1998;100-101:149-153.
53. Stevens RJ, Rusch D, Davies PA, et al. Molecular properties important for inhaled anesthetic action on human 5-HT3A receptors. Anesth Analg. 2005;100:1696-1703.
54. + channel activities in cultured human alveolar epithelial cells. Mol Pharmacol. 2006;69: 1755-1762.
55. Turner LA, Fujimoto K, Suzuki A, et al. The interaction of isoflurane and protein kinase C-activators on sarcolemmal KATP channels. Anesth Analg. 2005;100:1680-1686.
56. Chen X, Sirois JE, Lei Q, et al. HCN subunit-specific and cAMP-modulated effects of anesthetics on neuronal pacemaker currents. J Neurosci. 2005;25:5803-5814.
57. Sanders RD, Maze M. Alpha2-adrenoceptor agonists. Curr Opin Investig Drugs. 2007;8:25-33.
58. Nelson LE, Lu J, Guo T, et al. The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology. 2003;98:428-436.
59. Nelson LE, Guo TZ, Lu J, et al. The sedative component of anesthesia is mediated by GABA(A) receptors in an endogenous sleep pathway. Nat Neurosci. 2002;5:979-984.
60. Bol CJ, Vogelaar JP, Mandema JW. Anesthetic profile of dexmedetomidine identified by stimulus-response and continuous measurements in rats. J Pharmacol Exp Ther. 1999;291:153-160.
61. Souter MJ, Rozet I, Ojemann JG, et al. Dexmedetomidine sedation during awake craniotomy for seizure resection: effects on electrocorticography. J Neurosurg Anesthesiol. 2007;19:38-44.